1. Home
  2. BCAB vs SRBK Comparison

BCAB vs SRBK Comparison

Compare BCAB & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • SRBK
  • Stock Information
  • Founded
  • BCAB 2007
  • SRBK 1887
  • Country
  • BCAB United States
  • SRBK United States
  • Employees
  • BCAB N/A
  • SRBK N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • SRBK
  • Sector
  • BCAB Health Care
  • SRBK
  • Exchange
  • BCAB Nasdaq
  • SRBK Nasdaq
  • Market Cap
  • BCAB 22.3M
  • SRBK 117.4M
  • IPO Year
  • BCAB 2020
  • SRBK N/A
  • Fundamental
  • Price
  • BCAB $0.39
  • SRBK $13.48
  • Analyst Decision
  • BCAB Buy
  • SRBK
  • Analyst Count
  • BCAB 2
  • SRBK 0
  • Target Price
  • BCAB $1.00
  • SRBK N/A
  • AVG Volume (30 Days)
  • BCAB 520.0K
  • SRBK 122.6K
  • Earning Date
  • BCAB 08-07-2025
  • SRBK 07-25-2025
  • Dividend Yield
  • BCAB N/A
  • SRBK 0.74%
  • EPS Growth
  • BCAB N/A
  • SRBK N/A
  • EPS
  • BCAB N/A
  • SRBK N/A
  • Revenue
  • BCAB $11,000,000.00
  • SRBK $27,988,000.00
  • Revenue This Year
  • BCAB N/A
  • SRBK N/A
  • Revenue Next Year
  • BCAB N/A
  • SRBK N/A
  • P/E Ratio
  • BCAB N/A
  • SRBK N/A
  • Revenue Growth
  • BCAB N/A
  • SRBK 23.80
  • 52 Week Low
  • BCAB $0.24
  • SRBK $9.12
  • 52 Week High
  • BCAB $2.53
  • SRBK $13.65
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 45.46
  • SRBK 58.70
  • Support Level
  • BCAB $0.36
  • SRBK $13.00
  • Resistance Level
  • BCAB $0.40
  • SRBK $13.54
  • Average True Range (ATR)
  • BCAB 0.04
  • SRBK 0.18
  • MACD
  • BCAB -0.00
  • SRBK 0.04
  • Stochastic Oscillator
  • BCAB 22.73
  • SRBK 80.82

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About SRBK SR Bancorp Inc. Common stock

SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.

Share on Social Networks: